Nanoconjugates able to cross the blood-brain barrier
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-048/00
A61K-047/48
A61K-049/18
C12N-015/113
A61K-047/69
출원번호
US-0344576
(2012-09-14)
등록번호
US-9889209
(2018-02-13)
국제출원번호
PCT/US2012/055635
(2012-09-14)
§371/§102 date
20140711
(20140711)
국제공개번호
WO2013/040499
(2013-03-21)
발명자
/ 주소
Mirkin, Chad A.
Ko, Caroline H.
Stegh, Alexander
Giljohann, David A.
Luciano, Janina
Jensen, Samuel A.
출원인 / 주소
NORTHWESTERN UNIVERSITY
대리인 / 주소
Marshall, Gerstein & Borun LLP
인용정보
피인용 횟수 :
0인용 특허 :
222
초록
The present disclosure is directed to nanoconjugates that cross the blood-brain barrier and methods of their therapeutic use.
대표청구항▼
1. A method of treating a patient suffering from Glioblastoma multiforme, comprising administering to the patient a therapeutically effective amount of a composition comprising a functionalized nanoconjugate having a mass that is at least about 1 kilodalton, the nanoconjugate comprising a surface-at
1. A method of treating a patient suffering from Glioblastoma multiforme, comprising administering to the patient a therapeutically effective amount of a composition comprising a functionalized nanoconjugate having a mass that is at least about 1 kilodalton, the nanoconjugate comprising a surface-attached polynucleotide having a sequence sufficiently complementary to a target polynucleotide to hybridize to and inhibit expression of the target polynucleotide, wherein the target polynucleotide is a Bcl-2 family member, and wherein the administration is not intracranial administration and the nanoconjugate does not comprise a targeting moiety. 2. A method of administering a composition comprising a functionalized nanoconjugate having a mass that is at least about 1 kilodalton to a patient, the method comprising administering to the patient a therapeutically effective amount of the composition; wherein the nanoconjugate comprises a surface-attached polynucleotide having a sequence sufficiently complementary to a target polynucleotide to hybridize to and inhibit expression of the target polynucleotide, wherein the target polynucleotide is a Bcl-2 family member, wherein the administration is not intracranial administration and the nanoconjugate does not comprise a targeting moiety, and wherein the patient suffers from Glioblastoma multiforme and is in need of a composition that is able to traverse the blood-brain barrier. 3. The method of claim 1 wherein the composition further comprises a therapeutic agent. 4. The method of claim 1 wherein the composition is administered only once. 5. The method of claim 1 wherein the composition is administered at a frequency of no greater than about once per week. 6. The method of claim 1 wherein the patient is a human. 7. The method of claim 1 wherein the Bcl-2 family member is Bcl2L12. 8. The method of claim 1 wherein the nanoconjugate comprises a nanoparticle that is metallic. 9. The method of claim 2 wherein the nanoconjugate comprises a nanoparticle that is metallic. 10. The method of claim 8 wherein the nanoparticle is a gold nanoparticle. 11. The method of claim 9 wherein the nanoparticle is a gold nanoparticle. 12. The method of claim 1 wherein the administering is transdermal administering. 13. The method of claim 2 wherein the administering is transdermal administering. 14. The method of claim 1 wherein the polynucleotide is DNA or RNA. 15. The method of claim 14 wherein the polynucleotide is small interfering RNA (siRNA). 16. The method of claim 2 wherein the polynucleotide is DNA or RNA. 17. The method of claim 16 wherein the polynucleotide is small interfering RNA (siRNA). 18. The method of claim 1 wherein the nanoconjugate comprises a nanoparticle that is hollow. 19. The method of claim 2 wherein the nanoconjugate comprises a nanoparticle that is hollow. 20. The method of claim 1 wherein the nanoconjugate comprises a nanoparticle that is from about 5 nanometers (nm) to about 150 nm in mean diameter. 21. The method of claim 2 wherein the nanoconjugate comprises a nanoparticle that is from about 5 nanometers (nm) to about 150 nm in mean diameter. 22. The method of claim 1 wherein the polynucleotide is covalently associated with the nanoconjugate. 23. The method of claim 2 wherein the polynucleotide is covalently associated with the nanoconjugate. 24. The method of claim 1 wherein the polynucleotide is present on the surface of the nanoconjugate at a surface density of at least 0.3 pmol/cm2. 25. The method of claim 2 wherein the polynucleotide is present on the surface of the nanoconjugate at a surface density of at least 0.3 pmol/cm2. 26. The method of claim 1 wherein the polynucleotide is present on the surface of the nanoconjugate at a surface density of at least 2 pmol/cm2. 27. The method of claim 2 wherein the polynucleotide is present on the surface of the nanoconjugate at a surface density of at least 2 pmol/cm2. 28. The method of claim 1 wherein the polynucleotide is present on the surface of the nanoconjugate at a surface density of about 15 pmol/cm2. 29. The method of claim 2 wherein the polynucleotide is present on the surface of the nanoconjugate at a surface density of about 15 pmol/cm2. 30. The method of claim 3 wherein the therapeutic agent is temozolamide, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-4/5, a fibroblast growth factor (FGF), neurotrophin (NT)-3, erythropoietin (EPO), hepatocyte growth factor (HGF), epidermal growth factor (EGF), transforming growth factor (TGF)-α, TGF-β, vascular endothelial growth factor (VEGF), interleukin-1 receptor antagonist (IL-1ra), ciliary neurotrophic factor (CNTF), glial-derived neurotrophic factor (GDNF), neurturin, platelet-derived growth factor (PDGF), heregulin, neuregulin, artemin, persephin, an interleukin, granulocyte-colony stimulating factor (CSF), granulocyte-macrophage-CSF, cardiotrophin-1, hedgehog, leukemia inhibitory factor (LIF), midkine, pleiotrophin, a bone morphogenetic protein (BMP), netrin, saposin, semaphorin, or stem cell factor (SCF). 31. The method of claim 1 wherein the nanoconjugate has a mass that is about 2, about 3, about 5, about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 200, about 500, about 700, about 900 or more kilodaltons. 32. The method of claim 2 wherein the nanoconjugate has a mass that is about 2, about 3, about 5, about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 200, about 500, about 700, about 900 or more kilodaltons. 33. The method of claim 1, further comprising administering a therapeutic agent to the patient. 34. The method of claim 1 wherein the nanoconjugate comprises a nanoparticle that is from about 30 nm to about 100 nm. 35. The method of claim 1 wherein the nanoconjugate comprises a nanoparticle that is from about 40 nm to about 80 nm in mean diameter. 36. The method of claim 2 wherein the nanoconjugate comprises a nanoparticle that is from about 30 nm to about 100 nm. 37. The method of claim 2 wherein the nanoconjugate comprises a nanoparticle that is from about 40 nm to about 80 nm in mean diameter. 38. The method of claim 2 wherein the Bcl-2 family member is Bcl2L12.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (222)
Tkachuk Zenovy (Kiev SUX) Kvasyuk Eugeny (Kiev SUX) Matsuka Gennady (Kiev SUX) Mikhailopulo Igor (Kiev SUX), (2′-5′) oligoadenylate analogues useful as inhibitors of host-v5.-graft response.
Huynh Dinh Tam (Croissy/Seine FRX) Gouyette Catherine (Vanves FRX) Igolen Jean (Le Mesnil St. Denis FRX), 2,N6-disubstituted and 2,N6-trisubstituted adenosine-3′-phosphoramidites.
Suhadolnik Robert J. (Roslyn PA) Pfleiderer Wolfgang (Constance DEX), 2′,5′-phosphorothioate oligoadenylates and their covalent conjugates with polylysine.
Cook Philip D. (Carlsbad CA) Delecki Daniel J. (Radnor PA) Guinosso Charles (Vista CA), Acyclic nucleoside analogs and oligonucleotide sequences containing them.
Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR) Stirchak Eugene P. (Corvallis OR), Alpha-morpholino ribonucleoside derivatives and polymers thereof.
Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA) Vasseur Jean J. (San Marcos CA) Debart Francoise (Montpellier FRX), Backbone modified oligonucleotide analogues.
Sanghvi Yogesh S. (San Marcos CA) Cook Phillip D. (Vista CA), Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Ramsay Shaw Barbara (Durham NC), Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Bertsch-Frank Birgit (Rheinfelden DEX) Klasen Claas-Juergen (Freigericht DEX) Lieser Thomas (Hapau DEX) Mueller Klaus (Hasselroth DEX) Bewersdorf Martin (Gelnhausen DEX), Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions.
Ohtsuka Eiko (Sappro JPX) Inoue Hideo (Sappro JPX) Morisawa Hirokazu (Kawasaki JPX) Shibahara Susumu (Kawasaki JPX) Mukai Sachiko (Kawasaki JPX) Nishihara Tohru (Kurashiki JPX), Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and st.
Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), DNA-reporter conjugates linked via the 2′or 5′-primary amino group of the 5′-terminal nucleoside.
Baxter Anthony D. (Northwich GB2) Baylis Eric K. (Stockport GB2) Collingwood Stephen P. (Westhoughton GB2) Taylor Roger J. (Stretford GB2) De Mesmaeker Alain (Kanerkinden CHX) Schmit Chantal (Basel C, Dinucleoside phosphinates and their pharmaceutical compositions.
Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
Froehler Brian (Belmont CA) Wagner Rick (Belmont CA) Matteucci Mark (Burlingame CA) Jones Robert J. (Millbrae CA) Gutierrez Arnold J. (Sandy Lane CA) Pudlo Jeff (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines.
Weis Alexander L. (Berwyn PA) Oakes Fred T. (Rochester NY) Hausheer Frederick H. (San Antonio TX) Cavanaugh ; Jr. Paul F. (West Chester PA) Moskwa Patricia S. (Phoenixville PA), Exonuclease resistant terminally substituted oligonucleotides.
Rogers Thomas E. (Manchester MO) Gray Steven H. (Ellisville MO) Devadas Balekudru (Chesterfield MO) Adams Steven P. (St. Charles MO), Improved probes using nucleosides containing 3-dezauracil analogs.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke Shee L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Denkewalter Robert G. (Westfield NJ) Kolc Jaroslav (Randolph Twp. ; Morris County NJ) Lukasavage William J. (Harrison NJ), Macromolecular highly branched homogeneous compound based on lysine units.
Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
Magda Darren (Cupertino CA) Sessler Jonathan L. (Austin TX) Iverson Brent L. (Austin TX) Sansom Petra I. (Austin TX) Crofts Shaun P. (Campbell CA), Method of expanded porphyrin-oligonucleotide conjugate synthesis.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA) Eder Paul S. (Iowa City IA) Dagle John M. (Iowa City IA), Methods for blocking the expression of specifically targeted genes.
Froehler Brian ; Wagner Rick ; Matteucci Mark ; Jones Robert J. ; Gutierrez Arnold J. ; Pudlo Jeff, Methods of using oligomers containing modified pyrimidines.
Matteucci Mark (Burlingame CA) Jones Robert J. (Daly City CA) Munger John (San Francisco CA), Modified internucleoside linkages having one nitrogen and two carbon atoms.
Chad A. Mirkin ; Robert L. Letsinger ; Robert C. Mucic ; James J. Storhoff ; Robert Elghanian, Nanoparticles having oligonucleotides attached thereto and uses therefor.
Chad A. Mirkin ; Robert L. Letsinger ; Robert C. Mucic ; James J. Storhoff ; Robert Elghanian, Nanoparticles having oligonucleotides attached thereto and uses therefor.
Chad A. Mirkin ; Robert L. Letsinger ; Robert C. Mucic ; James J. Storhoff ; Robert Elghanian, Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert, Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A.; Garimella, Viswanadham; Li, Zhi, Nanoparticles having oligonucleotides attached thereto and uses therefor.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A., Nanoparticles having oligonucleotides attached thereto and uses thereof.
Davis Frank F. (19 Farmingdale Rd. East Brunswick NJ 08816) Van Es Theodorus (313 Overbrook Rd. Piscataway NJ 08854) Palczuk Nicholas C. (45 W. Franklin St. Bound Brook NJ 08805), Non-immunogenic polypeptides.
Lin Kuei-Ying (Fremont CA) Matteucci Mark (Burlingame CA), Non-nucleoside linkers for convenient attachment of labels to oligonucleotides using standard synthetic methods.
Shizuya Hiroaki (1632 Indiana Ave. South Pasadena CA 91030) Millar Sharon L. (1825 Lanai St. West Covina CA 91792), Non-radioisotope tagging of fragments.
Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
Nguyen Thanh T. (Tigy FRX) Helene Claude (Saint Cyr en Val FRX) Asseline Ulysse (La Source FRX), Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis a.
Weis Alexander L. (Berwyn PA) Oakes Fred T. (Rochester NY) Hausheer Frederick H. (San Antonio TX) Cavanaugh ; Jr. Paul F. (West Chester PA) Moskwa Patricia S. (Phoenixville PA), Nuclease resistant compounds.
Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA), Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression.
Swaminathan Sundaramoorthi ; Matteucci Mark ; Jones Robert J. ; Pudlo Jeff ; Munger John, Nuclease stable and binding competent oligomers and methods for their use.
Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA), Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled.
Hogan James (San Diego CA) Smith Richard (San Diego CA) Kop Joann (San Marcos CA), Nucleic acid probes for detection and/or quantitation of non-viral organisms.
Buhr Chris (Daly City CA) Matteucci Mark (Burlingame CA) Bischofberger Norbert W. (San Carlos CA) Froehler Brian (Belmont CA), Nucleoside 5′-methylene phosphonates.
Froehler Brian C. (Belmont CA) Buhr Chris A. (Daly City CA), Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues.
Klevan Leonard (Washington DC) Gebeyehu Gulilat (Silver Spring MD) Rao Prasad Y. (Damascus MD), Nucleotide analogs for nucleic acid labeling and detection.
Meyer ; Jr. Rich B. (Woodinville WA) Adams A. David (Snohomish WA) Petrie Charles R. (Woodinville WA), Oligo (aa
상세보기
Letsinger Robert L. (Wilmette IL) Gryaznov Sergei M. (San Mateo CA), Oligodeoxyribonucleotides including 3′-aminonucleoside-phosphoramidate linkages and terminal 3′-amino groups.
Bischofberger Norbert (San Carlos CA) Kent Ken (Mountain View CA) Wagner Rick (Burlingame CA) Buhr Chris (Daly City CA) Lin Kuei-Ying (Fremont CA), Oligonucleotide analogs capable of passive cell membrane permeation.
Weis Alexander Ludvik (Berwyn PA) Hausheer Frederick Herman (San Antonio TX) Chaturvedula Prasad Venkata Chala (Exton PA) Delecki Daniel Joseph (Radnor PA) Cavanaugh ; Jr. Paul Francis (West Chester , Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleo.
Warren ; III Harold C. (Rush NY) Oakes Fred T. (Rochester NY), Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction proce.
Haralambidis Jim (Box Hill South AUX) Tregear Geoffrey W. (Hawthorn AUX), Oligonucleotide-polyamide conjugates and methods of production and applications of the same.
Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), Oligonucleotides possessing a primary amino group in the terminal nucleotide.
Lebleu Bernard (Montpellier FRX) Bayard Bernard (Castelnau Le Lez FRX), Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini.
Imbach Jean-Louis (Montpellier FRX) Gosselin Gilles J. M. (Montpellier FRX), Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Shaw Barbara R. (Durham NC), Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates.
Meyer ; Jr. Rich B. (Woodinville WA) Gall Alexander A. (Bothell WA) Reed Michael W. (Seattle WA), Peptide linkers for improved oligonucleotide delivery.
Misiura Konrad (Lodz PLX) Gait Michael (Cambridge GB3), Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic.
Maddry Joseph A. (Birmingham AL) Reynolds Robert C. (Birmingham AL) Secrist John A. (Birmingham AL) Montgomery John A. (Birmingham AL) Crooks Peter A. (Lexington KY), Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages.
Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO) Brill Wolfgang (Freiburg DEX) Nielsen John (Horsholm DKX), Polynucleotide phosphorodithioate.
Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use.
Couvreur Patrick (Wezembeek-Oppem BEX) Roland Michel (Brussels BEX) Speiser Peter (Forch CHX), Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use.
Hawkins Mary E. (Potomac MD) Pfleiderer Wolfgang (Konstanz MD DEX) Davis Michael D. (Rockville MD) Balis Frank (Bethesda MD), Pteridine nucleotide analogs as fluorescent DNA probes.
Van Ness Jeffrey (Bothell WA) Petrie Charles R. (Woodinville WA) Tabone John C. (Bothell WA) Vermeulen Nicolaas M. J. (Woodinville WA), Solid supports for nucleic acid hybridization assays.
Gordon Julian (307 E. Sheridan Rd. Lake Bluft IL 60044) Minks Michael A. (Biochemistry Dept. ; University of the Witwatersrand ; 1 Jan Smuts Ave Johannesburg 2001 ZAX), Specific antibody to the native form of 2′5′-oligonucleotides, the method of preparation and the use as reagents in im.
Cook Phillip Dan (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA), Substituted purines and oligonucleotide cross-linking.
Burke Donald (Boulder CO) Tarasow Ted (Boulder CO) Eaton Bruce E. (Boulder CO) Gold Larry (Boulder CO), Systematic evolution of ligands by exponential enrichment: chimeric selex.
Sessler Jonathan L. (Austin TX) Mody Tarak D. (Sunnyvale CA) Hemmi Gregory W. (Sunnyvale CA), Texaphyrin metal complexes having improved functionalization.
Sessler Jonathan L. (Austin TX) Mody Tarak D. (Sunnyvale CA) Hemmi Gregory W. (Sunnyvale CA) Kral Vladimir A. (Austin TX) Magda Darren (Cupertino CA), Texaphyrin-oligonucleotide conjugates.
Reed Michael W. (3575 NE. 180th Seattle WA 98105) Meyer ; Jr. Rich B. (15411 NE. 176th Pl. Woodinville WA 98072), Trifunctional intermediates for preparing 3′-tailed oligonucleotides.
Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR), Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages.
Echauz, Javier Ramon; Esteller, Rosana; Litt, Brian; Vachtsevanos, George John, Unified probabilistic framework for predicting and detecting seizure onsets in the brain and multitherapeutic device.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.